Thyroid carcinoma, version 2.2014.


Journal Article

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

Full Text

Cited Authors

  • Tuttle, RM; Haddad, RI; Ball, DW; Byrd, D; Dickson, P; Duh, Q-Y; Ehya, H; Haymart, M; Hoh, C; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Waguespack, SG; Wang, TN; Wirth, LJ; Hoffmann, KG; Hughes, M

Published Date

  • December 2014

Published In

Volume / Issue

  • 12 / 12

Start / End Page

  • 1671 - 1680

PubMed ID

  • 25505208

Pubmed Central ID

  • 25505208

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2014.0169


  • eng

Conference Location

  • United States